A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 24 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated
- 29 Feb 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.